These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21747064)

  • 1. Primary prevention of coronary heart disease with statins: it's not about the money.
    Schwartz JS
    Circulation; 2011 Jul; 124(2):130-2. PubMed ID: 21747064
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
    Lazar LD; Pletcher MJ; Coxson PG; Bibbins-Domingo K; Goldman L
    Circulation; 2011 Jul; 124(2):146-53. PubMed ID: 21709063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: Statin use in the elderly.
    Raffel OC; White HD
    Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):318-28. PubMed ID: 16729010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Earlier translation of evidence into public subsidy may prevent morbidity and mortality: an example using statins in diabetics with normal cholesterol levels.
    Page MM; Sanfilippo FM; Geelhoed EA; Briffa TG; Hobbs MS
    Aust N Z J Public Health; 2012 Oct; 36(5):435-40. PubMed ID: 23025364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D; Unal B; Critchley J; Capewell S
    QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
    Idzior-Waluś B
    Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 17. A clinical focus on statins.
    Auer J; Eber B
    Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of statins in the prevention of coronary heart disease--potential side effects.
    Okuyama H; Ichikawa Y; Sun Y; Hamazaki T; Lands WE
    World Rev Nutr Diet; 2007; 96():55-66. PubMed ID: 17167280
    [No Abstract]   [Full Text] [Related]  

  • 19. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.